Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis
- PMID: 20689651
- PMCID: PMC2916180
Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis
Abstract
To investigate the association of expression and promoter methylation of tumor-suppressor genes with risk of ovarian cancer, we conducted a case-control study of 102 patients with serous epithelial ovarian cancer and 100 patients without ovarian cancers. We measured mRNA expression levels (by real-time reverse transcription polymerase chain reaction) and methylation status (by methylation-specific polymerase chain reaction) of five candidate genes (BRCA1, BRCA2, hMLH1, MGMT, and DNMT3B) in tumors from the cases and normal ovaries from the controls. We found that mRNA expression levels of the five genes were decreased in tumors than in normal ovaries with 0.39-fold for BRCA1, 0.25-fold for BRCA2, 0.42-fold for hMLH1, 0.45-fold for MGMT, and 0.87-fold for DNMT3B, calculated by the 2(-ΔΔCT) method. Ovarian cancer risk (odds ratios, ORs) was associated with low expression of all genes (2.95 [95% confidence interval (CI), 1.51 - 5.78] for BRCA1, 3.65 (95% CI, 1.82 - 7.30) for BRCA2, 5.25 (95% CI, 2.52 - 10.96) for hMLH1, and 4.72 (95% CI, 2.32 - 9.62) for MGMT) but not DNMT3B. However, methylation status was not associated with gene expression levels in the tumors, except for hMLH1 whose mean (± SD) gene expression was significantly lower in methylated (13.0 ± 7.6) than in unmethylated (31.2 ± 44.8) tumors (P < 0.001). We concluded that low mRNA expression of these tumor-suppressor genes, likely due to molecular mechanisms in addition to the promoter methylation in some instances, may be a biomarker for ovarian cancer risk in this study population. Larger studies are needed to validate our findings.
Figures

Similar articles
-
Inactivation of BRCA1 and BRCA2 in ovarian cancer.J Natl Cancer Inst. 2002 Sep 18;94(18):1396-406. doi: 10.1093/jnci/94.18.1396. J Natl Cancer Inst. 2002. PMID: 12237285
-
Expression and promoter methylation status of mismatch repair gene hMLH1 and hMSH2 in epithelial ovarian cancer.Aust N Z J Obstet Gynaecol. 2008 Oct;48(5):505-9. doi: 10.1111/j.1479-828X.2008.00892.x. Aust N Z J Obstet Gynaecol. 2008. PMID: 19032668
-
Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.Cancer Res. 2002 Jul 15;62(14):4151-6. Cancer Res. 2002. PMID: 12124354
-
Constitutional Mosaic Epimutations - a hidden cause of cancer?Cell Stress. 2019 Mar 22;3(4):118-135. doi: 10.15698/cst2019.04.183. Cell Stress. 2019. PMID: 31225507 Free PMC article. Review.
-
BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine.Clin Epigenetics. 2024 Dec 6;16(1):178. doi: 10.1186/s13148-024-01787-8. Clin Epigenetics. 2024. PMID: 39643918 Free PMC article. Review.
Cited by
-
A case of synchronous double primary breast carcinoma and osteosarcoma: Mismatch repair genes mutations as a possible cause for multiple early onset malignant tumors.Am J Case Rep. 2012;13:218-23. doi: 10.12659/AJCR.883382. Epub 2012 Sep 10. Am J Case Rep. 2012. PMID: 23569533 Free PMC article.
-
Association of prohibitin-1 and 2 with oxidative stress in rats with renal interstitial fibrosis.Mol Biol Rep. 2014 May;41(5):3033-43. doi: 10.1007/s11033-014-3162-1. Epub 2014 Mar 5. Mol Biol Rep. 2014. PMID: 24595445
-
Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer.Indian J Med Res. 2014 Nov;140(5):616-23. Indian J Med Res. 2014. PMID: 25579142 Free PMC article.
-
Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway.Mol Cell Biol. 2013 Jan;33(2):387-95. doi: 10.1128/MCB.00465-12. Epub 2012 Nov 12. Mol Cell Biol. 2013. PMID: 23149936 Free PMC article.
-
Reduced BRCA1 transcript levels in freshly isolated blood leukocytes from BRCA1 mutation carriers is mutation specific.Breast Cancer Res. 2016 Aug 17;18(1):87. doi: 10.1186/s13058-016-0739-8. Breast Cancer Res. 2016. PMID: 27534398 Free PMC article.
References
-
- Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2006;20:339–362. - PubMed
-
- Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol. 2006;20:207–225. - PubMed
-
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
-
- Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141–196. - PubMed
-
- Salozhin SV, Prokhorchuk EB, Georgiev GP. Methylation of DNA-one of the major epigenetic markers. Biochemistry (Mosc) 2005;70:525–532. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous